Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Hepatic lipase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepatic lipase (HL), also called hepatic triglyceride lipase (HTGL) or LIPC (for "lipase, hepatic"), is a form of lipase, catalyzing the hydrolysis of triacylglyceride. Hepatic lipase is coded by chromosome 15 and its gene is also often referred to as HTGL or LIPC. Hepatic lipase is expressed mainly in liver cells, known as hepatocytes, and endothelial cells of the liver. The hepatic lipase can either remain attached to the liver or can unbind from the liver endothelial cells and is free to enter the body’s circulation system. When bound on the endothelial cells of the liver, it is often found bound to HSPG, heparan sulfate proteoglycans (HSPG), keeping HL inactive and unable to bind to HDL (high density lipoprotein) or IDL (intermediate density lipoprotein). When it is free in the bloodstream, however, it is found associated with HDL to maintain it inactive. This is because the triacylglycerides in HDL serve as a substrate, but the lipoprotein contains proteins around the triacylglycerides that can prevent the triacylglycerides from being broken down by HL.
Novel ep4 agonist
ActiveUS20110098481A1Weaken agonist actionMaintaining blood concentrationBiocideOrganic chemistryCarbon numberHepatic lipase
Provided is a compound represented by the formula (1):wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and / or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
Owner:ASAHI GLASS CO LTD
Medicine composition for treating hepatic disease mainly
InactiveCN1985927AMeet urgent clinical needsSignificant effectOrganic active ingredientsDigestive systemHepatic lipaseFatty liver
The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition for treating liver diseases and its preparation process. The medicine composition is prepared with wolfberry fruit 50- 1000 weight portions, angelica 50-1000 weight portions, and glycyrrhizic acid or its pharmaceutically acceptable salt 1-50 weight portions; or with wolfberry fruit polysaccharide 2.5-50 weight portions, angelica polysaccharide 1-20 weight portions, and glycyrrhizic acid or its pharmaceutically acceptable salt 1-50 weight portions. It may be prepared into any pharmaceutically acceptable forms, preferably orally taken preparation and injection. It is used mainly for treating various liver diseases, including viral hepatitis, medicinal liver injury, fatty liver, alcohol liver, etc.
Owner:海安江理工技术转移中心有限公司
Method for lowering blood glucose and method for treating hepatic disease, obesity and diabetes
The present invention provides methods of administering a Dendrobium polyphenol in an amount effective to lower blood sugar, treat hepatic disease, obesity or diabetes. Exemplary hepatic disease includes fibrosis, fatty liver and hepatitis. Moreover, the Dendrobium polyphenol is extracted from the plants of the genus Dendrobium.
Owner:TUNGHAI UNIVERSITY
Method for Diagnosing Hepatic Diseases
The invention concerns a method for early diagnosis of hepatic diseases, which consists in determining in the samples of the diseased subjects, the presence of a apolipoprotein AI (Apo-AI) isoform, having oxidised W50, W108, and M112 residues. The inventive method is useful for diagnosing hepatocellular carcinoma and hepatitis B.
Owner:PROYECTO DE BIOMEDICINA CIMA
Method for simultaneously detecting 32 single nucleotide polymorphism (SNP) locus genotypes
InactiveCN101851672AImprove throughputEasy to operateMicrobiological testing/measurementHepatic lipaseAngiotensinogen mrna
The invention relates to a method for simultaneously detecting 32 labeled single nucleotide polymorphism (SNP) loci. In the method, adducin-1, platelet endothelial cell adhesion molecule-1 (PECAM-1), C-reactive protein (CRP), endothelial constitutive nitric oxide synthase (ecNOS), plasma cell membrane glycoprotein-1 (PC-1), L-selectin, G-protein beta3 subunit gene, angiotensin I converting enzyme (ACE), angiotensin II type 1 receptor gene, proangiotensin, methylenetetrahydrofolate reductase (MTHFR) and hepatic lipase gene which are published on an international haplotype diagram engineering database are selected for detecting 32 labeled single nucleotide polymorphisms of the Han nationality in China; three primers are designed for each single nucleotide polymorphism (two PCR amplification primers and one extension primer); and the single nucleotide polymorphism loci are subjected to genotyping through polymerase chain reaction (PCR) amplification, extension and hybridization and by applying an SNP stream genotyping system. The detection method has the advantages of quickness, accuracy, high throughput, simple operation, microscale and the like.
Owner:GENERAL HOSPITAL OF PLA
Prophylactic or therapeutic agent for hepatic diseases
ActiveCN104470531ACompounds screening/testingOrganic active ingredientsHepatic lipaseHepatic Diseases
Owner:宫崎彻
Methods and compositions for treating hepatic diseases
The invention provides methods and compositions for treating a hepatic disease, for reducing fat deposition in the liver and for inhibiting fibrosis of the liver by administering a compound or agent that modulates an adenosine receptor, in particular, an inhibitor or antagonist of an adenosine receptor, especially an A1 or A2B adenosine receptor antagonist.
Owner:NEW YORK UNIV
MiRNA expression model for diagnosing hepatic diseases independently
The invention relates to a miRNA expression model for diagnosing hepatic diseases independently. In the invention, an expression model of a miR-885-5p which is one of the circulating miRNAs associated with hepatic diseases is built by analyzing the types and relative expression levels of potential circulating miRNAs in a serum sample of a patient with cirrhosis or hepatocellular carcinoma and comparing the expression levels of the potential circulating miRNAs with the expression abundance of the circulating miRNAs in healthy reference serum. The model is formed by the expression indexes of the miR-885-5p, wherein the expression level of the miR-885-5p is higher than that of a healthy reference and is less tan 0.0001. ROC curve analysis shows that the hepatic disease HCC, LC and CHB identification efficacy AUC of the miR-885-5p and the healthy reference is 0.904, and the sensitivity and specificity of the miR-885-5p and the healthy reference are 90.5 percent and 79.2 percent respectively.
Owner:GENERAL HOSPITAL OF PLA
An application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease
PendingCN104825435ASolve usabilitySolve complexityOrganic active ingredientsDigestive systemDecenoic AcidHepatic lipase
The invention discloses an application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease, and relates to the technical field of applications of hydroxy-containing unsaturated compounds in which carboxyl is connected to a non-ring carbon. The hepatic disease relates to fatty liver, hepatitis or liver cirrhosis. The E-10-hydroxy-2-decenoic acid has definite treatment or aided treatment functions for the hepatic disease, can be used for preparation of the medicines or healthcare products which are used for treatment or aided treatment of the hepatic disease, and has advantages of low cost, good effects, low using amount, and no side or toxic effects.
Owner:SHIJIAZHUANG KANGNUO BIOTECH
Applications of protopanaxatriol and derivatives thereof in preparation of medicines for treating hepatic disease
ActiveCN104352505AGood anti-hepatic fibrosis activityWide range of usesOrganic active ingredientsDigestive systemHepatic lipaseHepatic Diseases
The invention discloses applications of protopanaxatriol derivatives or pharmaceutically formable salts thereof and protopanaxatriol or pharmaceutically formable salts of the protopanaxatriol in preparation of medicines for treating a hepatic disease. An in-vitro anti-liver fibrosis cell test proves that these compounds have relatively good anti-liver fibrosis activity, can be used as active components of anti-liver fibrosis medicines, and can be applied widely.
Owner:SHENZHEN SUN BIO SCI & TECH CO LTD
Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
Owner:LABYRINTH HLDG
EP4 agonist
ActiveUS8394844B2Weaken agonist actionMaintain concentrationBiocideOrganic chemistryCarbon numberHepatic lipase
Provided is a compound represented by the formula (1):wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1 -4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and / or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
Owner:ASAHI GLASS CO LTD
Application of betaine hydrochloride in preparing medicines and health foods for preventing and treating hepatic diseases
InactiveCN103800312AHas antiviral effectEasy chemical synthesisOrganic active ingredientsDigestive systemHepatic lipaseInterferon therapy
The invention discloses application of betaine hydrochloride in preparing medicines and health foods for preventing and treating hepatic diseases. Betaine hydrochloride is particularly used for preparing medicines and health foods for treating virus B hepatitis and hepatitis C, preparing sensitizers or synergists in viral disease treatment by interferon, preparing medicines or functional foods for reducing drug tolerance and the like occurring when hepatitis B is treated by nucleotide medicines, and preparing medicines or functional foods for protecting hepatic cells of hepatic diseases and reducing transaminase.
Owner:张晓元
Novel EP4 agonist
Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R and R each independently represents a hydrogen atom or a linear alkyl group having 1-3 carbon atoms, and R represents a hydrogen atom, an alkyl group having 1-4 carbon atoms, an alkoxyalkyl group, an aryl group, a halogen atom or a halogenated alkyl group) or a pharmaceutically acceptable salt thereof, which is different from publicly known PGIs and has a selective EP4 agonist action. Consequently, a pharmaceutical product which contains the compound is useful for prophylaxis and / or treatment of immune diseases, cardiovascular diseases, heart diseases, respiratory diseases, eye diseases, kidney diseases, hepatic diseases, bone diseases, digestive tract diseases, neurological diseases, skin diseases and the like.
Owner:ASAHI GLASS CO LTD
Compositions and methods for the treatment of hepatic diseases and disorders
Owner:LABYRINTH HLDG
Application of health care drinking liquid containing deep seawater in preparation of medicaments or health care products for preventing or treating hyperlipidemia
ActiveCN102652758ALower serum lipid levelsReduce the index of atherosclerosisMetabolism disorderInorganic active ingredientsHigh concentrationHepatic lipase
The invention provides an application of health care drinking liquid containing deep seawater in the preparation of medicaments or health care products for preventing or treating hyperlipoidemia. The health care drinking liquid comprises A liquid and B liquid, wherein the A liquid is of fresh water, the B liquid is of high-concentration concentrated liquid which is obtained by performing decompression concentration on a concentrated water part which is separated from the deep sweater via a reverse osmosis device, and the hardness range is 200-1000ppm. The health care drinking liquid is given to a rat with the hyperlipoidemia, which is subjected to modeling by a high-fat emulsion, in a free drinking way, after the medicament is administrated for 28 days, the blood lipid level of the rat with the hyperlipoidemia can be significantly reduced, lipid peroxidation can be inhibited, the activity of lipoprotein metabolic enzymes, namely LCAT (lecithin-cholesterol acetyltransferase), LPL (lipoprotein lipase) and HL (hepatic lipase), can be significantly improved, and the state of lipid metabolism disorder in the rat with the hyperlipoidemia, as well as concurrent fatty liver and diabetes thereof, can be further improved. The health care drinking liquid is derived from the deep seawater, has the advantages of abundant resources, easiness in industrialization and the like, and further has broad market and application prospects in the aspect of preventing and treating the hyperlipoidemia.
Owner:OCEAN UNIV OF CHINA
Novel medicine composition for treating hepatic diseases
InactiveCN1985988AFunction increaseAnti-hepatic fibrosisOrganic active ingredientsDigestive systemDiseaseHepatic lipase
The present invention belongs to the field of medicine technology, and is especially a kind of medicine composition and its preparation process. The medicine composition is prepared with kurarinone 4-400 weight portions, glutathione 3-300 weight portions, and tiopronin 1-100 weight portions. The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation. It has the pharmacological activities of antagonizing virus, improving liver cell function, antagonizing liver fibrosis, regulating immunity, diminishing inflammation, etc. and may be used in treating various hepatic diseases, viral hepatosis, medicinal hepatosis, alcoholic hepatosis, etc.
Owner:海安江理工技术转移中心有限公司
Preparation method of lipid-lowering corbicula fluminea shell powder compound feed
InactiveCN105166578AHigh activityLower visceral indexAnimal feeding stuffHepatic lipaseSerum triglycerides
The invention discloses a preparation method of a lipid-lowering corbicula fluminea shell powder compound feed. The preparation method specifically comprises the steps of firstly, adding corbicula fluminea shell powder into a basal feed for culturing fish, wherein the adding amount of the corbicula fluminea shell powder accounts for 0.75%-3.25% of the total weight of the basal feed; then uniformly mixing the basal feed, namely corbicula fluminea shell powder, to prepare particles, and drying to obtain the compound feed. The feed prepared by the invention can be used for not only lowering the index of the fish liver and serum triglyceride, but also obviously improving the activity of hepatic lipase.
Owner:HUNAN AGRICULTURAL UNIV
Prophylactic or therapeutic agent for hepatic diseases
ActiveUS9993524B2Effective to prophylaxis and treatmentEvaluating effectCompounds screening/testingOrganic active ingredientsHepatic lipaseHepatic Diseases
The present disclosure provides a prophylactic or therapeutic agent for a hepatic disease, containing AIM or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same. The present discloses also provides a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an animal obtained by loading a non-human mammal deficient in AIM expression with a high fat diet and the like.
Owner:CO THE INST FOR AIM MEDICINE TWINS
Application of composition in preparation of medicine for treating skin itching caused by hepatic diseases
InactiveCN106038519AMoisturizePlay protectiveHydroxy compound active ingredientsDigestive systemHepatic lipaseHepatic Diseases
The invention discloses an application of a composition in preparation of a medicine for treating skin itching caused by hepatic diseases, wherein the composition is composed of medicinal alcohol and glycerol in a volume ratio of (3-1):1. The composition is formed by simply mixing alcohol and glycerol, does not generate any newborn substance, has a good effect on treating skin itching caused by hepatic diseases, does not cause irritation to skin itching caused by hepatic diseases, and can also play a role in protecting the skin.
Owner:BEIJING DITAN HOSPITAL CAPITAL MEDICAL UNIV +1
Medicinal and edible composition for hepatic disease with malnutrition, as well as preparation and preparation application of medicinal and edible composition
InactiveCN106729186AGreat tasteSweet and sour tasteDispersion deliveryDigestive systemHepatic lipaseAdditive ingredient
The invention belongs to the field of medicine compositions and particularly relates to a medicinal and edible composition for treating a hepatic disease with malnutrition, a preparation and a preparation application. The composition comprises the following ingredients: Chinese wolfberries, Chinese yams, hawthorns, malt and semen raphani. The traditional Chinese medicine preparation comprises the medicinal and edible composition as an active ingredient and an auxiliary material. A reagent kit comprises traditional Chinese medicine preparation reagent units, wherein an effective dose of the medicinal and edible composition of each reagent unit is 0.1-3g. The invention further provides the application of the medicinal and edible composition or the traditional Chinese medicine preparation or the reagent kit in the field of preparing a medicine for treating the hepatic disease with the malnutrition or the field of preparing a health care product or food for protecting a liver. The medicinal and edible composition has multiple effects of supplementing nutrients, improving a liver function, improving an appetite and relieving abdominal distention, is good in safety and taste and low in price, and has obvious advantages in nutritional supplementation for a patient with the hepatic disease.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV
Reagent used for measuring pancreatic lipase in serum or plasma, and preparation method and application thereof
InactiveCN109580515AReduce interferenceImprove featuresMaterial analysis by observing effect on chemical indicatorColor/spectral properties measurementsHepatic lipaseProtamine sulfate
The invention relates to the technical field of biochemical detection, in particular to a reagent used for measuring pancreatic lipase in serum or plasma, and a preparation method and application thereof. The invention provides pancreatic lipase measurement reagent which comprises sodium dodecyl sulfate, protamine sulfate and sphingomyelin. Since the sodium dodecyl sulfate, the protamine sulfate and the sphingomyelin are added into the pancreatic lipase measurement reagent, the interference function of hepatic lipase, lipoprotein lipase and cholesterol esterase in the serum for pancreatic lipase measurement can be obviously lowered, nonspecific lipolysis reaction in the serum or the plasma in a reaction process of the pancreatic lipase measurement can be effectively inhibited, meanwhile, the catalytic activity of the pancreatic lipase can guarantee to be effectively performed, pancreatic lipase measurement specificity and accuracy is improved, and the false positive rate of pancreaticlipase detection is effectively lowered.
Owner:BIOSINO BIO TECH & SCI
Methods for predicting and detecting intolerance to an hypolipidemic agent
InactiveUS20100087462A1Eliminate side effectsMaximizing a desired plasma lipid reductionBiocideOrganic active ingredientsHepatic lipaseGlycerol
The invention describes methods and tools for the identification of drug intolerance into subjects receiving an hypolipidemic agent. The invention further describes methods and tools for the prediction of drug intolerance in subjects in need of hypolipidemic agents. Some aspects of the invention are based on the assessment of the subject plasma glycerol concentrations. Some aspects of the invention are based on the assessment of the subject HDL-triglycerides concentration. Some other aspects are based on the identification of hepatic lipase gene variants in a subject genome.
Owner:BOREAL PHARMA RECH CLINIQUE
Purpose of lachnum melanin serving as blood fat-reducing medicament
InactiveCN107569520ASignificant hypolipidemic functionNo side effectsOrganic active ingredientsMetabolism disorderSerum glutamate pyruvate transaminaseHepatic lipase
Owner:HEFEI UNIV OF TECH
Dry powder type immobilized lipase and production process thereof
ActiveCN107815445AEasy to useHigh catalytic activityHydrolasesOn/in organic carrierHepatic lipaseImmobilized lipase
The invention provides dry powder type immobilized lipase and a production process thereof and particularly provides dry powder type immobilized pig live lipase. The dry powder type immobilized pig live lipase contains pig liver lipase and immobilized carrier resin, wherein the pig liver lipase is adhered to the immobilized carrier resin; and the water content (weight) of the dry powder type immobilized pig live lipase is 40%-50%. The invention further provides a preparation method of the dry powder type immobilized pig live lipase. The immobilized pig live lipase can present extremely high catalytic activity in an organic phase, is good in stability and can be repeatedly used.
Owner:ABIOCHEM BIOTECHNOLOGY (CHONGQING) CO LTD
The use of the yellow thorn fruit to improve lipid metabolism disorder
ActiveCN104983771BReduced activityHigh activityMetabolism disorderCardiovascular disorderHepatic lipaseDyslipidemia
Owner:CHINA ACAD OF SCI NORTHWEST HIGHLAND BIOLOGY INST
Application of 2,3,5,4'-tetrahydroxy diphenyl ethylene-2-1-beta-D-glucoside for preparation of drug reducing blood fat
InactiveCN1257176CGood hypolipidemic effectOrganic active ingredientsSugar derivativesHepatic lipaseMedicine
The present invention relates to a kind of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside for reducing blood lipid, which is characterized in that it has the function of inhibiting the increase of serum total cholesterol, reducing serum low The functions such as density lipoprotein cholesterol and improving the activity of liver lipase can be made into medicine with this active monomer.
Owner:广州中医药大学热带医学研究所
Novel medicine composition for treating hepatic diseases
InactiveCN1985988BMeet clinical needsGood antiviral effectOrganic active ingredientsDigestive systemHepatic lipaseLiver fibrosis
Owner:海安江理工技术转移中心有限公司
Application of health care drinking liquid containing deep seawater in preparation of medicaments or health care products for preventing or treating hyperlipidemia
ActiveCN102652758BReduce lipid accumulationLower fasting blood sugar levelsMetabolism disorderInorganic active ingredientsHepatic lipaseHigh concentration
The invention provides an application of health care drinking liquid containing deep seawater in the preparation of medicaments or health care products for preventing or treating hyperlipoidemia. The health care drinking liquid comprises A liquid and B liquid, wherein the A liquid is of fresh water, the B liquid is of high-concentration concentrated liquid which is obtained by performing decompression concentration on a concentrated water part which is separated from the deep sweater via a reverse osmosis device, and the hardness range is 200-1000ppm. The health care drinking liquid is given to a rat with the hyperlipoidemia, which is subjected to modeling by a high-fat emulsion, in a free drinking way, after the medicament is administrated for 28 days, the blood lipid level of the rat with the hyperlipoidemia can be significantly reduced, lipid peroxidation can be inhibited, the activity of lipoprotein metabolic enzymes, namely LCAT (lecithin-cholesterol acetyltransferase), LPL (lipoprotein lipase) and HL (hepatic lipase), can be significantly improved, and the state of lipid metabolism disorder in the rat with the hyperlipoidemia, as well as concurrent fatty liver and diabetes thereof, can be further improved. The health care drinking liquid is derived from the deep seawater, has the advantages of abundant resources, easiness in industrialization and the like, and further has broad market and application prospects in the aspect of preventing and treating the hyperlipoidemia.
Owner:OCEAN UNIV OF CHINA
Application of yellow thorn fruits to treating dyslipidemia
ActiveCN104983771AReduced activityHigh activityMetabolism disorderFood preparationDyslipidemiaHepatic lipase
The invention provides application of yellow thorn fruits or extracts of the fruits to preparing medicines or health care products or food for treating dyslipidemia. The research shows that the yellow thorn fruits have the effect of treating the dyslipidemia, and cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and rising high-density lipoprotein (HDL) can be reduced; the enzymatic activity relevant to lipid metabolism can be improved, that is, the activity of the lipoprotein lipase and hepatic lipase can be improved; meanwhile, the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase can be reduced, no hurt to the liver tissue exists, and the fruits can be used as the good-safety medicines or the health care products or the food for treating the dyslipidemia.
Owner:CHINA ACAD OF SCI NORTHWEST HIGHLAND BIOLOGY INST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com